Article

Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease

2023-07-31

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold> Prasinezumab, a monoclonal antibody that binds aggregated alpha-synuclein, is currently being investigated as a potential disease-modifying therapy in early-stage Parkinson’s disease (PD). In the PASADENA Phase II study, prasinezumab-treated individuals exhibited slower progression of motor signs than placebo-treated participants (MDS-UPDRS Part III). Here, we ex...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5103a8f2-d9a8-545f-b401-198d41775b8f
DOI: 10.21203/rs.3.rs-3128098/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s diseaseDOI 10.21203/rs.3.rs-3128098/v1Read

Disease‑Modifying Therapies for Parkinson’s Disease: Biological Mechanisms, Pharmacological Strategies, and Clinical PipelineSemantic proximity Read

Baseline α-synuclein seeding activity and disease progression in sporadic and genetic Parkinson’s disease in the PPMI cohortSemantic proximity Read

A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 Mutation.Semantic proximity Read

Faster reaction times of CSF Alpha-Synuclein Seed Amplification Assay predict the Diffuse Malignant subtype of Parkinson’s Disease at 10-year follow-upSemantic proximity Read

Disease‑Modifying Trials in Parkinson’s Disease: Challenges, Lessons, and Future DirectionsSemantic proximity Read

Promising disease-modifying therapies for Parkinson's disease.Semantic proximity Read

Progression in the LRRK2-Asssociated Parkinson Disease Population.Semantic proximity Read

Longitudinal relationships between non-motor symptoms and biomarkers as a function of motor symptom asymmetry in early Parkinson’s diseaseSemantic proximity Read

Impact of Age at Onset on Symptom Profiles, Treatment Characteristics and Health-Related Quality of Life in Parkinson’s DiseaseSemantic proximity Read

Safety and Feasibility of Serial Lumbar Punctures: Long-term Results from the Parkinson’s Progression Markers InitiativeSemantic proximity Read

Greater motor progression in patients with Parkinson disease who carry LRRK2 risk variants.Semantic proximity Read

Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation.Semantic proximity Read